Introduction
The selective activation of nontoxic prodrugs offers the potential of novel anti-cancer strategies by gene-directed enzyme prodrug therapy (GDEPT). This requires expression of a gene encoding an enzyme which does not affect cells in the absence of the prodrug, but is able to convert an inactive prodrug to a cytotoxin. Targeted cells are thus specifically susceptible to killing by the prodrug. This approach has also proved useful in studies in transgenic mice where the selective ablation of cells has been used to address basic questions of cellular physiology and development. During the past decade, herpes simplex virus type 1 thymidine kinase (HSV1tk) has attracted most attention both with respect to anti-cancer applications [1] [2] [3] [4] [5] and targeted cell ablation in transgenic mice. 6, 7 HSV1-tk phosphorylates a variety of nucleoside analogs, such as ganciclovir (GCV) and acyclovir (ACV), which kill the cells by disruption of DNA replication. 8 Recently, however, a new inducible cell-specific ablation system, which appears to have significant advantages over HSVtk, has been described by ourselves 9 and others. 10, 11 This system is based on the E. coli enzyme nitroreductase (NTR) which activates the aziridine compound CB1954 (5-aziridin-1-yl-2,4-dinitrobenzamide), to a potent cytotoxic agent. The activated prodrug is thought to induce DNA interstrand cross-linking at a high frequency leading to cell death 12 which is not dependent on cell proliferation.
In a previous study we developed a model to study selective cell ablation in vivo in the mammary gland by generating transgenic mice in which the expression of the NTR gene was targeted to the secretory epithelial cells using promoter sequences from the ovine milk protein gene, beta-lactoglobulin (BLG). 9 Mice expressing NTR in the mammary gland and treated with CB1954 showed extensive ablation of these cells when examined 48 h after administration of the prodrug. This is a fairly rapid response and compares favourably with the use of HSVtk in vivo where it can take between 1 and 2 weeks for any observed effects on ablation to manifest. 13 Nevertheless, for applications such as cell lineage analysis in early development an even narrower window of effective cell killing may be required. We also showed that NTR-CB1954-mediated cell killing was via apoptosis, consistent with a mechanism involving DNA cross-linking and occurred without major inflammatory effects in the mammary gland. 9 Interestingly, no obvious bystander effects were observed in these experiments, in contrast to reports by other workers in cell culture. 14 The oncosuppressor gene p53 is one of the crucial factors in DNA-damage induced apoptosis. [15] [16] [17] NTR-CB1954-mediated apoptotic cell death in the mammary gland coincides with an up-regulation of p53 expression 18 raising the question whether or not this process is p53 dependent. P53 dependence would have important implications for any proposed anti-cancer therapy involving NTR-CB1954, since disruption of the p53 gene is the most frequent genetic event associated with human cancer. 19 In this report we investigate the role of p53-mediated apoptosis in NTR-CB1954-mediated ablation of mammary luminal epithelial cells in vivo using NTR transgenic mice with a p53 null background. We show that NTRmediated cell death by CB1954 is extremely rapid -evident just a few hours after CB1954 administration and is independent of p53 gene function. 
Results
Nitroreductase-CB1954-induced cell apoptosis occurs as early as 7 h after prodrug administration Prodrug CB1954 was injected intraperitoneally (i.p.) into both RED 40 female mice expressing high levels of BLG-NTR transgene in the mammary gland and nontransgenic control mice on lactation day 6. The mammary tissues were then analysed at various time-points (see Materials and methods). No discernable effects on the overall structure, size or the histological appearance of the mammary glands were observed in the control mice at any of the time-points investigated (data not shown); 9 nor were changes observed in the mammary gland of mock-inoculated RED 40 mice. For RED 40 mice treated with prodrug CB1954, no obvious changes were seen in the overall morphology of the gland at 7 h after administration (as evidenced by whole mounts), but by 17 h, the mammary glands were reduced in size (data not shown). This effect was more marked with the mammary glands taken at 24 h after administration of CB1954.
Histological examination of the CB1954-treated mammary glands showed that focal collapse of alveoli appeared as early as 7 h after CB1954 treatment ( Figure  1c ). By 17 h after CB1954 treatment, many more collapsed alveoli and apoptotic bodies were visible and the structure of mammary glands was disrupted (Figure 1e ). At 24 h after CB1954 administration, a heterogeneous disruption to the normal morphology of the gland was evident with distorted and shrunken lobules (Figure 1g ), an appearance which is similar to our previous results. 9 No inflammation was apparent. Apoptotic cell staining using 'apoTag' confirmed these very rapid effects and revealed a 10-fold increase in the number of apoptotic cells at 7 h after CB1954 administration compared with the control (Figure 1d ). The increase of apoptotic cells in the mammary gland was more evident at 17 h (Figure 1f ) but had dropped by 24 h after CB1954 administration ( Figure 2 ). We presumed it was due to rapid removal of apoptotic cells from the tissue which can occur within a few hours of cell death. 20 To exclude any effects of involution of the mammary tissues in these experiments, all treated mice were carefully monitored for feeding their pups. Experiments were also performed in which the pups were removed from nontreated RED 40 females at lactation days 6 or 7 and the mammary glands were analysed histologically 24, 48 and 72 h after. No changes were observed at 24 h although collapsed alveoli were evident at 48 h and became devastating at 72 h after removing the pups (data not shown). These morphological changes appeared homogenously throughout the gland in contrast to the CB1954-NTR-mediated effects which showed cell death was patchy reflecting the variegated expression of the BLG-NTR transgene as we have previously reported. 9, 18 NTR-CB1954-induced cell apoptosis is p53 independent It has been shown that CB1954 can increase p53 expression in both NTR-transfected cell lines and in the secretory epithelial cells in the mammary gland of BLG-NTR transgenic mice. 18 To investigate whether NTR-CB1954-induced cell apoptosis was p53 dependent, RED 40 mice were crossed with a 'knock-out' mouse strain carrying a p53 null allele 17 and female progeny resulting from two sequent crosses were genotyped by PCR ( Figure 3 ) and ablation studies were carried out. Extensive cell death was observed in the mammary gland of BLG-NTR transgenic mice after CB1954 treatment irrespective of whether or not they carried a functional p53 gene. The results are summarised in Table 1 . The five BLG-NTR transgenic mice without a functional p53 gene (NTR+, p53−/−) in this study showed various levels of ablation in the mammary gland after CB1954 treatment. Three of them (11.3, 13.2, 12.10) did not produce enough milk to feed their pups after the third inoculation and four of them (except 11.13) showed an obvious visual macroscopic reduction in size of mammary glands when whole mounts were examined (not shown). Histological examination of CB1954-treated RED40-p53 null (NTR+, p53−/−) mice revealed a heterogenous disruption of the mammary tissue (Figure 4a ) compared with the normal morphology of the gland (Figure 4b ) and similar to that observed for the CB1954-treated RED40-p53 wild-type (NTR+, p53+/+) mice. The heterogenous pattern of ablation corresponded to the pattern of NTR transgene expression (Figure 4c) . In situ apoptotic cell staining confirmed that apoptotic cells appeared at a higher frequency in the CB1954-treated glands of RED40-p53 null mice (Figure 4e ) compared with the controls (Figure 4f ). Neither mock-treated RED40-p53 null mice nor nontransgenic p53-deficient mice treated with CB1954 exhibited any ablation in the mammary gland (Figure 4b, d and f). Immunostaining with NTR antibody on mouse 11.13, which only had restricted ablation by CB1954, showed only a few small focal areas of transgene expression, indicating that low ablation level was due to the highly patchy expression of the transgene. Livers from mice of any genotype were unaffected by CB1954 treatment (data not shown). Table 1 . Discussion NTR-mediated cell death by CB1954 is a very rapid event In our previous report we showed that the induction of cell death by CB1954 in NTR expressing cells was dosage dependent. Lactating animals given single or triple doses of CB1954 at 50 mg/kg body weight exhibited considerably more cell death in the mammary gland than animals given a 10 mg/kg body weight dosage and at a dosage of 2 mg/kg body weight, little or no effect of the prodrug was observed. 9 To characterise the system further, here we report the time-course of cell ablation by CB1954 in vivo in the mammary gland of transgenic mice. The experiments show that NTR-mediated cell death in the luminal cells of mammary gland by CB1954 occurs at least as early as 7 h after only one injection of CB1954. By 24 h after injection, the effects are quite well advanced and are not due to involution effects per se as these effects are only manifest later and in a homogenous pattern. These effects are extremely rapid when compared with HSV1tk-based systems for cell ablation where cell killing can take many days or even weeks. 7, 13 This rapid response indicates that it may be possible to use the CB1954-NTR approach to target cell death in situations where there is a narrow window of time such as in early development.
mt). Mice having only wt amplimer are p53 wild type (lanes 11-16), having only mt amplimer are p53 null (lanes 1-10) and those having both amplimers are p53 heterozygous (lane 17). (b). PCR for BLG-NTR transgene: the amplimer is 463 bp nitroreductase cDNA (NTR). All the mice except lanes 8-10, 17 have BLG-NTR transgene. The genotype of the mice are summarised in
The time required to achieve cell death in the two systems may reflect the different mechanisms on which they are based. HSV1tk-mediated cell killing by ganciclovir (GCV) or acyclovir (ACV) requires cell proliferation in most cases 6 so that the phosphorylated products of GCV or ACV can be incorporated into cellular DNA during replication and this kills cells by chain termination. By contrast, NTR-mediated cell killing by CB1954 does not require cell proliferation. The activated CB1954 crosslinks DNA which presumably triggers the apoptosis cascade, resulting in rapid cell death.
Functional p53 is not required for NTR-CB1954-induced cell apoptosis The p53 tumour suppressor protein is a potent inhibitor of cell growth and transformation and acts as a sensor for DNA damage in a number of cell types. It initiates a sequence of events which causes cells to arrest in G1 21 or to die by apoptosis. [15] [16] [17] 22 After irradiation or chemicallyinduced DNA damage, wild-type p53 rapidly accumulates in the cell nucleus. A number of experiments have shown that wild-type p53 can mediate DNA damageinduced programmed cell death. 23 NTR-mediated cell death by CB1954 increases the expression of wild-type p53, both in vitro and in vivo. 18 To understand more fully the mechanism of CB1954-NTR-mediated cell death it is thus essential to know whether p53 is required. By crossing BLG-NTR transgenic mice with a p53-deficient mouse strain we generated a mouse strain which expressed NTR in the luminal cells of the mammary gland during gestation and lactation but lacked functional p53. Our results showed that activated CB1954 induced cell death in the p53 null mice in a manner indistinguishable at a morphological level to that in p53 wild-type mice, showing that functional p53 is not required for CB1954-NTR-mediated cell death. However, our experiments cannot exclude an involvement of functional p53 in this cell killing system by a second p53-dependent pathway.
Although CB1954-NTR-mediated cell death clearly occurs in p53 null mice our results indicate that the degree of ablation in these mice was, in general, lower than in their p53 wild-type littermates (Table 1) . Thus, five of six of the wild-type p53 mice showed extensive ablation whereas four of five of the p53 null mice showed only moderate or restricted cell death after 72 h. Although we cannot exclude possible p53-dependent effects, the variance in the cell death is thought most likely to be due to different levels of mosaic expression of the transgene since non-disrupted alveolar structures do not express NTR. Notwithstanding this point, the fact that specific and effective killing by NTR-CB1954 does not require a functional p53, provides additional support for using this system in GDEPT approaches to cancer as it will be effective against tumours which have deleted p53 genes.
Materials and methods
Production of BLG-NTR transgenic mice lacking the p53 gene Transgenic RED 40 female mice express NTR specifically in the luminal epithelial cells of the mammary gland under the control of the sheep ␤-lactoglobulin promoter. 9 Homozygous males from this line were mated with heterozygous p53-deficient female mice that had been generated by inserting a neo cassette into the p53 gene. 17 The genotype of the progeny was identified by polymerase chain reaction. For the BLG-NTR transgene, the PCR reaction was carried out 1 min each at 94°C, 62°C and 72°C for 30 cycles with the upstream primer 5Ј-GCA-GATCAAAACGCTACTGCAATAC-3Ј and downstream primer 5Ј-AGCCTTTCTCTTTCAGACCAAATTC-3Ј. Three primers were used for screening both p53 wild-type and the mutant gene which has been described previously. 24 Mice which were heterozygous for both BLG-NTR transgene and the p53 mutant gene were subsequently crossed to generate BLG-NTR mice on a wild-type, heterozygous and p53 null background which were identified by PCR (Figure 3) . Female mice of the appropriate genotype were selected and mated so as to obtain mammary gland tissue expressing the NTR gene.
CB1954 administration CB1954 was suspended in arachis oil containing 10% acetone at a concentration of either 3 mg/ml or 5 mg/ml. The suspension was warmed to 37°C before injection. For the time-course study, RED 40 adult female mice were injected with a single dose of CB1954 at 50 mg/kg body weight i.p. or mock injected on lactation day 6. The mice were then killed at 7, 17 and 24 h after the injection and mammary tissues were collected. Non-transgenic control female mice were also treated with CB1954 in the same manner as the transgenic mice.
In the p53 study, female mice aged 10-12 weeks with various genotypes were mated to stud males and CB1954 administered i.p. three times at 30 mg/kg body weight on lactation days 4 to 6; mice of the same genotypes were also mock injected as control. The mice were killed 24 h after the last injection and mammary glands and liver tissues were collected for analysis. In some cases the female mice failed to feed their pups after only two injections of CB1954 indicating an early failure of lactation (Table 1) . In these cases, the tissues were collected immediately so as to prevent involution in the mammary gland.
Histology and immunohistochemistry
Mammary tissues were fixed in neutral buffered formalin and embedded in paraffin before sectioning. Five-micron sections were cut for staining. Sections were stained using haematoxylin and eosin. To assess the degree of ablation, sections were viewed by two observers at low (40×) magnification. The proportion of ablation was determined by estimating the area of mammary tissue exhibiting ablation over the area of total mammary tissue in the sections. Sections were stained for NTR according to a validated protocol. 9 In situ apoptosis was detected using the ApoTag kit (Oncor, ST100 kit) following the manufacturer's instructions as described previously. 9 The level of apoptosis was quantified by counting positive staining cells within a field of view at a magnification of 400×. A total of six randomly chosen ablated fields were counted per experimental mouse, and for the control, six fields showing at least one positive staining cell were selected. University) for provision of the p53 deficient mouse strain. An MRC ROPA award funded this work.
